First reported case of safe and efficacious use of tocilizumab for treatment of hyperinflammatory syndrome associated with COVID-19 in an allogeneic stem cell transplant patient.
作者信息
Fordham Nicholas, Baker Emma, Forton Daniel, Klammer Matthias, Patel Kamal, Qadir Dara, Reyal Yasmin, Willis Fenella, Koh Mickey B C
机构信息
Haematology Department St George's University Hospitals NHS Foundation Trust London UK.
St Catherine's College University of Oxford Oxford UK.
出版信息
EJHaem. 2020 Dec 8;2(1):143-146. doi: 10.1002/jha2.132. eCollection 2021 Feb.
Abstract
摘要
相似文献
1
First reported case of safe and efficacious use of tocilizumab for treatment of hyperinflammatory syndrome associated with COVID-19 in an allogeneic stem cell transplant patient.
EJHaem. 2020 Dec 8;2(1):143-146. doi: 10.1002/jha2.132. eCollection 2021 Feb.
2
Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
J Med Virol. 2020 Nov;92(11):2516-2522. doi: 10.1002/jmv.26038. Epub 2020 Jun 9.
3
Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone.
Front Pharmacol. 2022 May 30;13:866441. doi: 10.3389/fphar.2022.866441. eCollection 2022.
4
The Treatment of COVID-19 Purgatory Syndrome With Tocilizumab and Steroids.
Cureus. 2022 Feb 25;14(2):e22614. doi: 10.7759/cureus.22614. eCollection 2022 Feb.
5
Potential Benefits of Tryptophan Metabolism to the Efficacy of Tocilizumab in COVID-19.
Front Pharmacol. 2020 Jun 19;11:959. doi: 10.3389/fphar.2020.00959. eCollection 2020.
6
Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
Lancet Oncol. 2014 Dec;15(13):1451-1459. doi: 10.1016/S1470-2045(14)71017-4. Epub 2014 Nov 14.
7
Successful treatment of acute heart failure in COVID-19-induced cytokine storm with tocilizumab: a case report.
Eur Heart J Case Rep. 2020 Jul 17;4(FI1):1-6. doi: 10.1093/ehjcr/ytaa188. eCollection 2020 Oct.
8
First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia.
Front Med (Lausanne). 2020 Nov 16;7:596916. doi: 10.3389/fmed.2020.596916. eCollection 2020.
9
Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report.
J Med Case Rep. 2020 Oct 15;14(1):187. doi: 10.1186/s13256-020-02503-9.
10
Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.
Acta Med Indones. 2021 Apr;53(2):194-201.
本文引用的文献
1
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients.
Natl Sci Rev. 2020 Jun;7(6):998-1002. doi: 10.1093/nsr/nwaa041. Epub 2020 Mar 13.
2
Effective treatment of severe COVID-19 patients with tocilizumab.
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
3
COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine.
Am J Transplant. 2020 Jul;20(7):1902-1906. doi: 10.1111/ajt.15935. Epub 2020 May 13.
4
COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
Nat Rev Immunol. 2020 May;20(5):271-272. doi: 10.1038/s41577-020-0312-7.
5
Tocilizumab treatment in COVID-19: A single center experience.
J Med Virol. 2020 Jul;92(7):814-818. doi: 10.1002/jmv.25801. Epub 2020 Apr 15.
6
First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab.
Blood Adv. 2020 Apr 14;4(7):1307-1310. doi: 10.1182/bloodadvances.2020001907.
7
COVID-19: consider cytokine storm syndromes and immunosuppression.
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
8
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.
Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3.
9
Clinical Characteristics of Coronavirus Disease 2019 in China.
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
10
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.
J Thromb Haemost. 2020 Apr;18(4):844-847. doi: 10.1111/jth.14768. Epub 2020 Mar 13.
Zotero 插件